Amnis Therapeutics

aneugraft® Dx
Pericardium Covered Stent

CE 0344

PERICARDIUM COVERED STENT (PCS)

INSTRUCTIONS FOR USE

STERILE - Ethylene Oxide Sterilized.

For single use only. Do not re-sterilize.

THE CLINICAL TECHNIQUES AND PROCEDURES DESCRIBED HERE DO NOT REPRESENT ALL MEDICALLY ACCEPTED CORONARY STENT IMPLANTATION PROCEDURES NOR ARE THEY INTENDED AS A SUBSTITUTE FOR THE PHYSICIAN EXPERIENCE, BUT ARE OFFERED TO CLINICIANS AS A GUIDE.

1. DESCRIPTION

AneugraftDx PCS (Figure 1) consists of one flexible laser cut stent (made of implantable high grade surgical stainless steel 316L) combined with one piece of pericardial tissue that has been selected for minimal tissue blemishes. The tissue is treated with a glutaraldehyde process, which cross links the collagen fibers and minimizes antigenicity and is attached to the stent with polypropylene suture.

The stent assembly is mounted on a balloon catheter, specially designed for tortuous vessels, that hosts the AneugraftDx stent design. AneugraftDx PCS is ethylene oxide sterilized.



Figure 1: AneugraftDx PCS

2. HOW SUPPLIED

AneugraftDx PCS is packaged in a balloon catheter dispenser and then placed in a medical pouch, suitable for EO sterilization. It is finally packaged in the AneugraftDx PCS box. The sterility is maintained inside of the pouch unless the pouch is damaged or opened.

This product is intended for single use only. Do not resterilize. Doing so may damage the balloon catheter or tissue cover and render the product unfit for use. Do not use if the pouch is damaged or opened.

Box Content:

- One (1) AneugraftDx stent in a sealed sterile pouch
- One (1) Flushing needle
- One (1) Instructions for Use manual

2.1 Storage

AneugraftDx PCS should be stored at temperatures between 4°C - 40°C (39°F - 104°F). **REFRIGERATION IS NOT REQUIRED**. **LONG TERM EFFECTS OF STENT FREEZING HAVE NOT BEEN STUDIED.**

3. COMPATIBILITY

AneugraftDx is compatible with the following:

- Guiding catheter with minimum I.D. 0.070" (1.78 mm)
- 0.014" (0.36 mm) guide wire
- large lumen "Y" connector (i.e. 0.125" (3.2 mm)

4. INDICATIONS

The balloon expandable AneugraftDx PCS is intended for intraluminal chronic placement after PTCA procedures that have been performed in coronary arteries, aorto-coronary bypass grafts, or suitable size vessels. It may be used for the following indications: Coronary Bypass-Vein Graft Stenosis, Coronary Bypass-Vein Graft Aneurysm. In emergency situations the device in all its sizes can also be used for: Acute Coronary Artery Perforation, Acute Coronary Artery Rupture, and Coronary Artery Aneurysm. However clinical studies have not been conducted for these emergency situations.

5. CONTRAINDICATIONS

AneugraftDx is contraindicated for the following patients:

Patients with hemorrhagic diathesis or other disorders in which the application of anticoagulant or antiplatelet therapy is contra-indicated (peptic ulceration, stroke complications, etc.); imminent thrombus formation and alteration of flow after myocardial infarction; Patients with proximal atherosclerosis and/or vessel in whom guidewire access and adequate guiding catheter support is prohibited; Treatment of an unprotected left main coronary artery lesion; Patients in whom adequate pre-dilatation of the lesion site is not possible; Patients in whom aorto-coronary bypass procedures are contra-indicated; Patients in whom the necessary medication is contra-indicated; direct stenting; severe allergic reaction to the contrast medium; severe allergic reaction to the stent materials.

The fixed pericardium used in making AneugraftDx PCS has no known contraindications.

6. POTENTIAL COMPLICATIONS AND ADVERSE EFFECTS

During the stent implantation, complications and adverse effects similar to those experienced during a standard PTCA or regular stent placement may occur. Groin hematoma, pseudoaneurysm, intracranial and gastrointestinal hemorrhages, cardiac arrhythmia, angina pectoris, acute myocardial infarction, side branch occlusion, vascular thrombosis, acute or sub acute closure of vessel, acute or sub acute closure of stent, distal emboli (air, particle, thrombus), vessel perforation, ventricular flutter and fibrillation, haemolysis, subscribed tissue reaction, fever, inflammation, spasm, hematuria, adverse effects related to drug protocol, death. The principal complications, which have been reported for pericardial tissue, are fibrosis and infection. These complications are observed only in a small minority of patients after implantation of the pericardial tissue and are minimized with the proper handling of the product.

7. DIRECTIONS FOR USE:

7.1 Prior to use:

- Select the correct AneugraftDx PCS (Pericardium Covered Stent) size as appropriate for the procedure being performed. For that purpose, use the AneugraftDx size chart (Figure 2)

Catalogue No.		Diameter [mm]	Balloon Length [mm]
DTS2513E	AneuGraftDx Equine Pericardium Covered stent 2.5 mm diameter & 13 mm length	2.5	13
DTS3013E	AneuGraftDx Equine Pericardium Covered stent 3.0 mm diameter & 13 mm length	3.0	13
DTS3513E	AneuGraftDx Equine Pericardium Covered stent 3.5 mm diameter & 13 mm length	3.5	13
DTS4013E	AneuGraftDx Equine Pericardium Covered stent 4.0 mm diameter & 13 mm length	4.0	13
DTS2518E	AneuGraftDx Equine Pericardium Covered stent 2.5 mm diameter & 18 mm length	2.5	18
DTS3018E	AneuGraftDx Equine Pericardium Covered stent 3.0 mm diameter & 18 mm length	3.0	18
DTS3518E	AneuGraftDx Equine Pericardium Covered stent 3.5 mm diameter & 18 mm length	3.5	18
DTS4018E	AneuGraftDx Equine Pericardium Covered stent 4.0 mm diameter & 18 mm length	4.0	18
DTS2523E	AneuGraftDx Equine Pericardium Covered stent 2.5 mm diameter & 23 mm length	2.5	23
DTS3023E	AneuGraftDx Equine Pericardium Covered stent 3.0 mm diameter & 23 mm length	3.0	23
DTS3523E	AneuGraftDx Equine Pericardium Covered stent 3.5 mm diameter & 23 mm length	3.5	23
DTS4023E	AneuGraftDx Equine Pericardium Covered stent 4.0 mm diameter & 23 mm length	4.0	23
DTS2527E	AneuGraftDx Equine Pericardium Covered stent 2.5 mm diameter & 27 mm length	2.5	27
DTS3027E	AneuGraftDx Equine Pericardium Covered stent 3.0 mm diameter & 27 mm length	3.0	27
DTS3527E	AneuGraftDx Equine Pericardium Covered stent 3.5 mm diameter & 27 mm length	3.5	27
DTS4027E	AneuGraftDx Equine Pericardium Covered stent 4.0 mm diameter & 27 mm length	4.0	27

Figure 2: AneugraftDx size chart

- Carefully inspect the pouch for damage. **DO NOT USE AneugraftDx IF THE PACKAGE IS DAMAGED. Select a new one for the procedure.**
- Before opening the AneugraftDx package, examine the expiration date indicated on the pouch label. If the product has expired DO NOT USE THE PRODUCT. Select a NON expired product.
- After opening the pouch, carefully retrieve the stent from the balloon catheter dispenser. Inspect the balloon catheter and ensure it is free of kinks.
- Do not remove the stent from the delivery balloon – removal may damage the stent and/or lead to stent embolization. The stent system is intended to perform as a system. Stent manipulation (e.g., rolling the mounted stent with your fingers) may loosen the stent from the delivery system balloon and cause dislodgment.
- Using the needle provided, flush the guide wire lumen with clean saline twice.
- Mount the balloon catheter with the AneugraftDx covered stent on the coronary guide wire and advance just proximal to the haemostatic valve.

7.2PreDilation

AneugraftDx PCS is not intended for direct stenting. Pre-dilate the lesion with a balloon of appropriate size prior to using AneugraftDx PCS.

7.3 Delivery Process

- Introduce the balloon mounted AneugraftDx through the valve. Do not use “push button” like hemostatic valves. Fully open the hemostatic valve. Introduce and retrieve the tip of a vessel dilator to ensure adequate opening of the valve.
- Slowly advance while flushing gently with contrast to avoid air being aspirated into the guiding catheter.
- As soon as the proximal end of the balloon has reached the hub of the guiding catheter, verify under fluoroscopy that no air bubbles are inside the guiding catheter.
- DO NOT inject contrast material or saline while the AneugraftDx is still inside the guiding catheter. Injections of saline or contrast should be done only once the covered stent has exited the guiding catheter.
- Confirm adequate guiding catheter position and advance the AneugraftDx to the desired site for deployment following the hospital standard procedure for stent implantation.

- Expansion of the stent should be performed according to the table below (Figure 3):

Pressure (atm)	Ø2.5	Ø3.0	Ø3.5	Ø4.0
4	2.47	2.97	3.47	3.97
* 5	2.50	3.00	3.50	4.00
6	2.53	3.03	3.53	4.03
7	2.57	3.06	3.56	4.06
8	2.60	3.10	3.60	4.10
9	2.64	3.14	3.64	4.14
10	2.68	3.18	3.68	4.18
11	2.71	3.22	3.72	4.21
12	2.75	3.25	3.75	4.25
13	2.79	3.29	3.79	4.28
14	2.83	3.33	3.83	4.32
15	2.87	3.37	3.87	4.36
16	2.91	3.41	3.91	4.40
17		3.45	3.95	4.45
18		3.50	4.00	4.50
19		3.56	4.06	4.56
20		3.62	4.12	4.62

* Minimum deployment pressure. Full stent opening ≤ 9 atm .

Nominal Pressure
Rated Burst Pressure (RBP)

Figure 3

The nominal pressure in the compliance chart specifically relates to the inflation pressure versus diameter characteristics of the balloon. Therefore, applicable only during the inflation process and until the stent reaches its fully opened state to the overhang section between the stent edge and the balloon shoulder. Once the stent reaches its fully opened state, the chart is applicable to the entire balloon/stent segment.

After the stent has reached its target site and is positioned correctly across the lesion (using balloon catheter radio-opaque markers which indicate the location of the covered stent) stent inflation takes place, due to the common dogbone effect, as follows:

- First phase: The unconstrained balloon catheter edges inflate ("edges first" shape, as shown in the Figure 4 below).
- Second phase: The covered stent is fully opened.



Figure 4: The AneugraftDx Inflation Process ("edges first" shape)

- **Do not attempt to pull an unexpanded stent back through the guiding catheter, as dislodgment of the stent from the balloon may occur** Should **unusual resistance** be felt **at any time** during either lesion access or removal of the stent delivery system before stent implantation, the entire system **should be removed as a single unit.**

Before withdrawing the delivery system, visually confirm complete balloon deflation by fluoroscopy. Failure to do so may cause vessel / arterial damage.

OVERSTRETCHING AneugraftDx PCS WILL SERIOUSLY DAMAGE THE COVERING TISSUE. If further to deployment expansion or high-pressure inflation is needed, use a second balloon of suitable size and proceed as on a regular stent but NOT exceeding the stent nominal diameter by more than indicated in the table below. Do NOT inflate the provided balloon above the maximum allowed pressure.

Use the following reference compliance table:

NOMINAL DIAMETER (mm)	MAXIMUM DIAMETER (mm)
2.5	2.9
3.0	3.5
3.5	4.0
4.0	4.6

8.WARNINGS

- AneugraftDx is for SINGLE USE ONLY.
- All persons responsible for the handling and preparation of AneugraftDx PCS must exercise utmost care to avoid damaging it.
- Do not handle AneugraftDx PCS with traumatic forceps.
- Do not attempt to re-sterilize an AneugraftDx PCS.
- Do NOT inflate the provided balloon above the maximum allowed pressure.
- Do not expose AneugraftDx PCS to steam, ethylene oxide, chemical or radiation (gamma/electron beam) sterilization.

- The implantation of a coronary stent requires advanced technical skills and experience in coronary angioplasty procedures. It is beyond the scope of these Instructions for Use manual to instruct the physician in specific PTCA procedures. Amnis Therapeutics Ltd assumes that any interventional cardiologist performing the above procedures has received adequate training and is thoroughly familiar with the pertinent scientific literature.
- AneugraftDx PCS should be used only by physicians (interventional cardiologists), specifically trained in coronary stent implantation. The medical techniques and procedures described here do not represent all medically accepted coronary stent implantation procedures, nor are they intended as a substitute for the physician's training and experience, but are offered to clinicians as a guide.
- Stent placement should only be performed at hospitals where emergency coronary artery bypass graft surgery can be readily performed. Administration of appropriate medication is critical to successful stent implantation and follow-up in order to minimize potential complications and adverse effects. Guidelines for an appropriate medication protocol before, during and after stent implantation should be based on experiences and routine in your clinic. Post procedural treatment with anti-thrombotics should be at least for 3 months. This device is not intended as a direct stenting device. Previous artery balloon dilatation is recommended.

9. PRECAUTIONS

- A review of the existing literature shows that the AneugraftDx PCS is MR conditional at field strengths of 3 Tesla (T) or less.
- Do not perform Magnetic Resonance Imaging (MRI) scan on patients' post-stent implantation until the stent has been completely endothelialized (eight weeks) to minimize the potential for migration. The stent may cause artifacts in MRI scans due to distortion of the magnetic field.
- At this time, the long-term durability of fixed pericardial tissue is unknown. The clinical advantages in using this material along with its known characteristics must be weighed against its current undetermined long-term durability.
- To avoid the possibility of dissimilar metal corrosion, do not implant stents of different materials in tandem where overlap or contact is possible
- The use of Tandem stents in aneurysms has not been verified.
- Do not induce a vacuum on the delivery system prior to reaching the target lesion.

9. DISCLAIMER OF WARRANTS

AMNIS THERAPEUTICS LTD WARRANTS THAT REASONABLE CARE HAS BEEN USED IN THE DESIGN AND MANUFACTURE OF THIS DEVICE. THIS WARRANTY IS IN LIEU OF AND EXCLUDES ALL OTHER WARRANTIES NOT EXPRESSLY SET FORTH HEREIN, WHETHER EXPRESSED OR IMPLIED BY OPERATION OF LAW OR OTHERWISE, INCLUDING, BUT NOT LIMITED TO, ANY IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. HANDLING, STORAGE, CLEANING AND STERILIZATION OF THIS DEVICE AS WELL AS OTHER FACTORS RELATING TO THE PATIENT, DIAGNOSIS, TREATMENT, IMPLANTATION PROCEDURES AND OTHER MATTERS BEYOND AMNIS THERAPEUTICS LTD´S CONTROL DIRECTLY AFFECT THIS DEVICE AND THE RESULTS OBTAINED FROM ITS USE. AMNIS THERAPEUTICS LTD'S OBLIGATION UNDER THIS WARRANTY IS LIMITED TO THE REPAIR OR REPLACEMENT OF THIS DEVICE, AND AMNIS THERAPEUTICS LTD SHALL NOT BE LIABLE FOR ANY INCIDENTAL OR CONSEQUENTIAL LOSS, DAMAGE OR EXPENSE DIRECTLY OR INDIRECTLY ARISING FROM THE USE OF THIS DEVICE. AMNIS THERAPEUTICS LTD ASSUMES NO LIABILITY WITH RESPECT TO DEVICES REUSED, REPROCESSED OR RESTERILIZED AND MAKES NO WARRANTIES, EXPRESSED OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE WITH RESPECT TO SUCH DEVICE. AMNIS THERAPEUTICS LTD NEITHER ASSUMES, NOR AUTHORIZES ANY OTHER PERSON TO ASSUME FOR IT, ANY OTHER OR ADDITIONAL LIABILITY OR RESPONSIBILITY IN CONNECTION WITH THIS DEVICE.

SYMBOLS

	ATTENTION: SEE IFU		STORE BETWEEN 4°C-40°C (39°F-104°F)	GW	GUIDEWIRE	GC	GUIDING CATHETER
	USE BY DATE	STERILE EO	STERILIZED BY ETHYLENE OXIDE (EO)	LOT	LOT NUMBER		MANUFACTURER
	SINGLE USE ONLY	RX	RAPID EXCHANGE	REF	CATALOG NUMBER		DO NOT USE IF PACKAGE IS DAMAGED
	DO NOT RE-STERILIZE						

Manufacturer:

Amnis Therapeutics Ltd.
22 Ha'ilan St., Or Akiva, 3060000, Israel
Phone: +972-722-200-330
Fax: +972-722-200-346
e-mail: info@amnis.life
www.amnis.life

EC REP

EC Authorized Representative:

Merc S.r.l.
Via Elia Capriolo, 41
25122 Brescia, Italy
Phone +39 030 2754021
e-mail: info@merc21.it

May be protected by one or more patents in the United States, Europe, China, Australia and Canada. Patents Pending in the United States, Europe and other countries. Please contact Amnis Therapeutics Ltd for further information.

Aneugraft and Over and Under are among the trademarks or registered trademarks owned by or licensed to Amnis Therapeutics Ltd or its subsidiaries in the United States, Europe and other countries. All other brand and product names are or may be trademarks of, and are used to identify products or services of, their respective owners.